Reporting owner · CIK 0001793971

Aurora Daljit Singh

SEC Form 4 history for the last 180 days across 1 company, 44 transactions and 2 filings.

SRSee RemarksNeumora Therapeutics, Inc.
Open-market transaction mix0% buys0 buys · 11 sales

Period: Last 180 days

Trade dates in this period: Aug 17, 2026 – Aug 21, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings2Form 4 records
Buying$00 purchases
Selling$702k11 sales
Net value−$702kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Aurora Daljit Singh transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$33.6kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$15.2kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$32.8kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$14.8kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$101kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$32.4kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$15.6kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$103kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$48.8kView disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
NMRANeumora Therapeutics, Inc.
SR
SR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Neumora Therapeutics, Inc. on Aug 21, 2026 valued at $33,599.57.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 2026011$0$701,641.09−$701,641.09

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$63.8k
Median P/S size$54.1k
Direct25
Indirect19
Aug 21, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

15 observations · Aug 17, 2026 – Aug 21, 2026. Window ends at the latest available report, not today.

Selected observation · Aug 21, 202648,750 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 17, 2026123,660Aug 19, 2026View transaction
Aug 17, 2026139,015Aug 19, 2026View transaction
Aug 17, 2026140,439Aug 19, 2026View transaction
Aug 17, 2026140,440Aug 19, 2026View transaction
Aug 17, 202682,770Aug 19, 2026View transaction
Aug 17, 202648,750Aug 19, 2026View transaction
Aug 18, 202682,912Aug 19, 2026View transaction
Aug 18, 202648,750Aug 19, 2026View transaction
Aug 19, 202662,018Aug 19, 2026View transaction
Aug 19, 202679,750Aug 19, 2026View transaction
Aug 19, 202648,750Aug 19, 2026View transaction
Aug 20, 2026116,491Aug 21, 2026View transaction
Aug 20, 202648,750Aug 21, 2026View transaction
Aug 21, 202669,303Aug 21, 2026View transaction
Aug 21, 202648,750Aug 21, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Aurora Daljit Singh Insider Activity FAQ

SEC Form 4 context

Who is Aurora Daljit Singh?

Aurora Daljit Singh is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001793971.

Which companies has Aurora Daljit Singh reported transactions for?

Neumora Therapeutics, Inc.

When was Aurora Daljit Singh's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Aurora Daljit Singh's latest insider sale?

The insider reported a sale at Neumora Therapeutics, Inc. on Aug 21, 2026 valued at $33,599.57.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.